These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 16574225)

  • 1. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
    Giles F; Verstovsek S; Faderl S; Vey N; Karp J; Roboz G; Khan KD; Cooper M; Bilgrami SF; Ferrant A; Daenen S; Karsten V; Cahill A; Albitar M; Kantarjian H; O'Brien S; Feldman E
    Leuk Res; 2006 Dec; 30(12):1591-5. PubMed ID: 16574225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
    Giles F; Rizzieri D; Karp J; Vey N; Ravandi F; Faderl S; Khan KD; Verhoef G; Wijermans P; Advani A; Roboz G; Kantarjian H; Bilgrami SF; Ferrant A; Daenen SM; Karsten V; Cahill A; Albitar M; Mufti G; O'Brien S
    J Clin Oncol; 2007 Jan; 25(1):25-31. PubMed ID: 17146105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
    Giles F; Verstovsek S; Thomas D; Gerson S; Cortes J; Faderl S; Ferrajoli A; Ravandi F; Kornblau S; Garcia-Manero G; Jabbour E; O'Brien S; Karsten V; Cahill A; Yee K; Albitar M; Sznol M; Kantarjian H
    Clin Cancer Res; 2005 Nov; 11(21):7817-24. PubMed ID: 16278404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.
    Schiller GJ; O'Brien SM; Pigneux A; Deangelo DJ; Vey N; Kell J; Solomon S; Stuart RK; Karsten V; Cahill AL; Albitar MX; Giles FJ
    J Clin Oncol; 2010 Feb; 28(5):815-21. PubMed ID: 20026800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cloretazine for the treatment of acute myeloid leukemia.
    Vey N; Giles F
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):321-8. PubMed ID: 16503849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
    Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.
    Gururangan S; Turner CD; Stewart CF; O'Shaughnessy M; Kocak M; Poussaint TY; Phillips PC; Goldman S; Packer R; Pollack IF; Blaney SM; Karsten V; Gerson SL; Boyett JM; Friedman HS; Kun LE
    Clin Cancer Res; 2008 Feb; 14(4):1124-30. PubMed ID: 18281546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.
    Zheng LM; Li Z; Liu L; Song BL; King I
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):45-51. PubMed ID: 17256135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laromustine (cloretazine).
    Vey N; Giles F
    Expert Opin Pharmacother; 2010 Mar; 11(4):657-67. PubMed ID: 20163276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
    Giles F; Thomas D; Garcia-Manero G; Faderl S; Cortes J; Verstovsek S; Ferrajoli A; Jeha S; Beran M; Koller C; Andreeff M; Cahill A; Clairmont C; Sznol M; Kantarjian H
    Clin Cancer Res; 2004 May; 10(9):2908-17. PubMed ID: 15131024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
    Morris KL; Adams JA; Liu Yin JA
    Leuk Res; 2009 Aug; 33(8):1096-9. PubMed ID: 19268363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
    Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
    J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
    Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
    Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission.
    Yanada M; Garcia-Manero G; Borthakur G; Ravandi F; Kantarjian H; Estey E
    Cancer; 2007 Dec; 110(12):2756-60. PubMed ID: 17948909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
    Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
    Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group.
    Koistinen P; Räty R; Itälä M; Jantunen E; Koivunen E; Nousiainen T; Pelliniemi TT; Remes K; Ruutu T; Savolainen ER; Siitonen T; Silvennoinen R; Volin L; Elonen E;
    Eur J Haematol; 2007 Jun; 78(6):477-86. PubMed ID: 17391337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
    Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
    Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.